Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®

被引：111

作者：

Kaku, Kohei ^{[1
]}

Lee, Jisoo ^{[2
]}

Mattheus, Michaela ^{[2
]}

Kaspers, Stefan ^{[2
]}

George, Jyothis ^{[3
]}

Woerle, Hans-Juergen ^{[2
]}

Aizenberg, D. ^{[4
]}

Ulla, M. ^{[5
]}

Waitman, J. ^{[6
]}

De Loredo, L. ^{[7
,8
]}

Farias, J. ^{[9
]}

Fideleff, H. ^{[9
]}

Lagrutta, M. ^{[10
]}

Maldonado, N. ^{[11
]}

Colombo, H. ^{[12
]}

Ferre Pacora, F. ^{[13
]}

Wasserman, A. ^{[14
]}

Maffei, L. ^{[15
]}

Lehman, R. ^{[16
]}

Selvanayagam, J. ^{[17
]}

d'Emden, M. ^{[18
]}

Fasching, P. ^{[19
]}

Paulweber, B. ^{[20
]}

Toplak, H. ^{[21
]}

Luger, A. ^{[22
]}

Drexel, H. ^{[23
]}

Prager, R. ^{[24
]}

Schnack, C. ^{[25
]}

Schernthaner, G. ^{[25
,26
]}

Fliesser-Goerzer, E.

Kaser, S. ^{[27
]}

Scheen, A. ^{[28
]}

Van Gaal, L. ^{[29
]}

Hollanders, G.

Kockaerts, Y. ^{[30
]}

Capiau, L.

Chachati, A. ^{[31
]}

Persu, A. ^{[32
]}

Hermans, M. ^{[32
]}

Vantroyen, D. ^{[33
]}

Vercammen, C. ^{[34
]}

Van de Borne, P. ^{[35
]}

Mathieu, C. ^{[36
]}

Benhalima, K. ^{[36
]}

Lienart, F. ^{[37
]}

Mortelmans, J.

Strivay, M. ^{[38
]}

Vereecken, G.

Keymeulen, B. ^{[39
]}

Lamkanfi, F. ^{[39
]}

机构：

[1] Kawasaki Med Sch, Dept Gen Internal Med, 577 Matsushima, Kurashiki, Okayama 7010192, Japan

[2] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[3] Boehringer Ingelheim Ltd, Bracknell, Berks, England

[4] Ctr Med Viamonte, Buenos Aires, DF, Argentina

[5] ILAIMCEOM, Cordoba, Cba, Argentina

[6] Ctr Diabetol Dr Waitman, Cordoba, Cba, Argentina

[7] Hosp Privado Ctr Med Cordoba SA, Cordoba, Cba, Argentina

[8] Parque Velez Sarfield, Cordoba, Cba, Argentina

[9] Sanatorio Guemes Hosp Privado, Buenos Aires, DF, Argentina

[10] Inst Invest Clin, Rosario, Santa Fe, Argentina

[11] Ctr Med Alta Complejidad, Rosario, Santa Fe, Argentina

[12] Clin Privada Colombo, Cordoba, Co, Argentina

[13] Ctr Med Colon, Cordoba, Co, Argentina

[14] Fepreva, Buenos Aires, DF, Argentina

[15] Consultorios Asociados Endocrinol & Invest Clin, Buenos Aires, DF, Argentina

[16] Adelaide Med Res, Ashford, SA, Australia

[17] Heart & Vasc Inst, Fullarton, SA, Australia

[18] Royal Brisbane & Womens Hosp, Herston, Qld, Australia

[19] Wilhelminenspital Wien, Vienna, Austria

[20] LKH Salzburg, St Johanns Spital, Salzburg, Austria

[21] Med Univ Graz, Graz, Austria

[22] Univ Klin Innere Med III, Vienna, Austria

[23] Landeskrankenhaus Feldkirch, Feldkirch, Austria

[24] Krankenhaus Hietzing NZR, Vienna, Austria

[25] Krankenanstalt Rudolfstiftung Wien, Semmelweis Frauenklin, Vienna, Austria

[26] Univ Klin Innere Med II, Vienna, Austria

[27] Univ Klin Innsbruck, Innsbruck, Austria

[28] Ctr Hosp Univ Liege, Liege, Belgium

[29] UZA, Edegem, Belgium

[30] Ziekenhuis Oost Limburg, Genk, Belgium

[31] CHR Huy, Huy, Belgium

[32] Clin Univ St Luc, Brussels, Belgium

[33] Huisartsenpraktijk Hygeia, Hasselt, Belgium

[34] Imelda ZH Bonheiden, Bonheiden, Belgium

[35] Hop Univ Erasme, Brussels, Belgium

[36] Univ Hosp Gasthuisberg, Leuven, Belgium

[37] CHU Tivoli, La Louviere, Belgium

[38] CHR Citadelle, Site Citadelle, Liege, Belgium

[39] UZ Brussels, Brussels, Belgium

[40] Hosp Sao Paulo UNIFESP, Villa Clementino, SP, Brazil

[41] Ctr Pesquisas Clin Ltda, Higienopolis, SP, Brazil

[42] Hosp Rim Hipertensao, Vila Clementino, SP, Brazil

[43] Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil

[44] Blumenau Serv Med SC Ltda, Vila Leopoldina, SP, Brazil

[45] Irmandade Santa Casa Misericordia Sao Paulo, Vila Albuquerque, SP, Brazil

[46] Hosp Guilherme Alvaro, Ctr Pesquisas Clin, Boqueirao, ST, Brazil

[47] Hosp Mae Deus, Porto Alegre, RS, Brazil

[48] Hosp Geral Goiania, Goiania, Go, Brazil

[49] FMUSP, Hosp Clin Sao Paulo, Sao Paulo, Brazil

[50] Univ Ribeirao Preto, Hosp Elect Bonini, Ribeirao Preto, Brazil

来源：

CIRCULATION JOURNAL | 2017年 / 81卷 / 02期

关键词：

Diabetes mellitus; Mortality; Race; Sodium-glucose cotransporter 2; Treatment outcomes; INHIBITION;

D O I：

10.1253/circj.CJ-16-1148

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: In the EMPA-REG OUTCOME (R) trial, empagliflozin added to standard of care reduced the risk of 3-point major adverse cardiovascular (CV) events (3-point MACE: composite of CV death, non-fatal myocardial infarction, or non-fatal stroke) by 14%, CV death by 38%, hospitalization for heart failure by 35%, and all-cause mortality by 32% in patients with type 2 diabetes (T2DM) and established CV disease. We investigated the effects of empagliflozin in patients of Asian race. Methods and Results: Patients were randomized to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo. Of 7,020 patients treated, 1,517 (21.6%) were of Asian race. The reduction in 3-point MACE in Asian patients was consistent with the overall population: 3-point MACE occurred in 79/1,006 patients (7.9%) in the pooled empagliflozin group vs. 58/511 patients (11.4%) in the placebo group (hazard ratio: 0.68 [95% confidence interval: 0.48-0.95], P-value for treatment by race interaction (Asian, White, Black/African-American): 0.0872). The effects of empagliflozin on the components of MACE, all-cause mortality, and heart failure outcomes in Asian patients were consistent with the overall population (P-values for interaction by race >0.05). The adverse event profile of empagliflozin in Asian patients was similar to the overall trial population. Conclusions: Reductions in the risk of CV outcomes and mortality with empagliflozin in Asian patients with T2DM and established CV disease were consistent with the overall trial population.

引用

页码：227 / +

页数：11

共 50 条

[41] Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
Cherney, David Z. I.
Zinman, Bernard
Inzucchi, Silvio E.
Koitka-Weber, Audrey
Mattheus, Michaela
von Eynatten, Maximilian
Wanner, Christoph
LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (08): : 610 - 621
[42] Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
Inzucchi, Silvio E.
Khunti, Kamlesh
Fitchett, David H.
Wanner, Christoph
Mattheus, Michaela
George, Jyothis T.
Ofstad, Anne Pernille
Zinman, Bernard
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (09): : 3025 - 3035
[43] THE INFLUENCE OF MICROVASCULAR DISEASE ON CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES: A POST HOC ANALYSIS OF EMPA-REG OUTCOME
Verma, Subodh
Wanner, Christoph
Zwiener, Isabella
Ofstad, Anne Pernille
George, Jyothis T.
Fitchett, David
Zinman, Bernard
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 2037 - 2037
[44] THE INFLUENCE OF MICROVASCULAR DISEASE ON CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES: A POST HOC ANALYSIS OF EMPA-REG OUTCOME
Verma, S.
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2019, 21 (0E) : E193 - E193
[45] Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
Ferreira, Joao Pedro
Verma, Subodh
Fitchett, David
Ofstad, Anne Pernille
Lauer, Sabine
Zwiener, Isabella
George, Jyothis
Wanner, Christoph
Zinman, Bernard
Inzucchi, Silvio E.
CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
[46] Empagliflozin Improves Cardiovascular (CV) Outcomes Regardless of Improvement in Cardiac and Vascular Hemodynamic Markers in Type 2 Diabetes Patients at High CV Risk in EMPA-REG OUTCOME
Chilton, Robert J.
Gullestad, Lars
Park, Sung-Ha
Fitchett, David
Silvio, E.
Hehnke, Uwe
Woerle, Hans Juergen
Johansen, Odd Erik
CIRCULATION, 2017, 136
[47] Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial
João Pedro Ferreira
Subodh Verma
David Fitchett
Anne Pernille Ofstad
Sabine Lauer
Isabella Zwiener
Jyothis George
Christoph Wanner
Bernard Zinman
Silvio E. Inzucchi
Cardiovascular Diabetology, 19
[48] Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial
Lund, S. S.
McGuire, D. K.
Zinman, B.
Inzucchi, S. E.
Anker, S. D.
Wanner, C.
Kaspers, S.
George, J. T.
Elsasser, U.
Woerle, H. J.
Fitchett, D.
DIABETOLOGIA, 2018, 61 : S324 - S325
[49] Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes?
Bajaj, Harpreet Singh
Zinman, Bernard
CANADIAN JOURNAL OF DIABETES, 2016, 40 (05) : 379 - 381
[50] Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME
Monteiro, P.
Schaper, N.
Clark, D.
Hantel, S.
Woerle, H. J.
Inzucchi, S. E.
Fitchett, D.
EUROPEAN HEART JOURNAL, 2016, 37 : 1191 - 1192

← 1 2 3 4 5 →